EA201990175A1 - COMBINED TREATMENT OF HEMATOLOGICAL ONCOLOGICAL DISEASES - Google Patents

COMBINED TREATMENT OF HEMATOLOGICAL ONCOLOGICAL DISEASES

Info

Publication number
EA201990175A1
EA201990175A1 EA201990175A EA201990175A EA201990175A1 EA 201990175 A1 EA201990175 A1 EA 201990175A1 EA 201990175 A EA201990175 A EA 201990175A EA 201990175 A EA201990175 A EA 201990175A EA 201990175 A1 EA201990175 A1 EA 201990175A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hematological
oncological diseases
combined treatment
inhibitor
imelstat
Prior art date
Application number
EA201990175A
Other languages
Russian (ru)
Inventor
Фей Хуан
Джошуа Дж. Расбелт
Александра Ризо
Original Assignee
Джерон Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джерон Корпорейшн filed Critical Джерон Корпорейшн
Priority claimed from PCT/US2017/044348 external-priority patent/WO2018026646A1/en
Publication of EA201990175A1 publication Critical patent/EA201990175A1/en

Links

Abstract

Изобретение относится к комбинированному лечению гематологических онкологических заболеваний. Более конкретно комбинация ингибитора теломеразы и ингибитора Bcl-2 полезна в лечении гематологических онкологических заболеваний, включая ОМЛ. В некоторых вариантах осуществления ингибитор теломеразы представляет собой иметельстат или иметельстат натрия, а ингибитор Bcl-2 представляет собой ABT-199.The invention relates to the combined treatment of hematological oncological diseases. More specifically, the combination of a telomerase inhibitor and a Bcl-2 inhibitor is useful in the treatment of hematologic oncological diseases, including AML. In some embodiments, the telomerase inhibitor is imelstat or sodium imelstat, and the Bcl-2 inhibitor is ABT-199.

EA201990175A 2016-11-16 2017-07-28 COMBINED TREATMENT OF HEMATOLOGICAL ONCOLOGICAL DISEASES EA201990175A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662422738P 2016-11-16 2016-11-16
PCT/US2017/044348 WO2018026646A1 (en) 2016-08-02 2017-07-28 Combination treatment for hematological cancers

Publications (1)

Publication Number Publication Date
EA201990175A1 true EA201990175A1 (en) 2019-08-30

Family

ID=67734921

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990175A EA201990175A1 (en) 2016-11-16 2017-07-28 COMBINED TREATMENT OF HEMATOLOGICAL ONCOLOGICAL DISEASES

Country Status (1)

Country Link
EA (1) EA201990175A1 (en)

Similar Documents

Publication Publication Date Title
CY1124311T1 (en) DNA-PK INHIBITORS
CY1125436T1 (en) DNA-PK INHIBITORS
CY1124061T1 (en) TRICYCLIC COMPOUND AS ANTICANCER AGENTS
EA201790413A1 (en) ANTIBODIES AGAINST TIGIT
EA201792354A1 (en) BATCHOLEIC ACID COMPOSITIONS AND METHODS OF APPLICATION
EA201591786A1 (en) GLA MONOTHERAPY FOR APPLICATION IN CANCER TREATMENT
EA201592074A1 (en) COMPOSITIONS AND METHODS OF CHANGING THE SIGNAL SYSTEM OF THE SECONDARY MESSENGER
EA201591616A1 (en) TRIFTTOROMETHYL-SUBSTITUTED ANNELATED PYRIMIDINES AND THEIR APPLICATION
EA201591591A1 (en) COMPOUNDS OF CARBAZOLE APPLIED AS Bromodomain Inhibitors
EA201591761A1 (en) COMPOSITIONS BASED ON NANOPARTICLES
EA201690456A1 (en) METHODS OF TREATMENT AND PREVENTION OF ENDOTHELIAL DYSFUNCTION WITH THE USE OF BARDOXOLON METHYL OR ITS ANALOGUES
CL2019002574A1 (en) Modulators of pcsk9 expression.
ZA202002779B (en) Dantrolene prodrugs and methods of their use
EA201500851A1 (en) ESTRA-1,3,5 (10), 16-TETRAEN-3-CARBOXAMIDES TO INHIBIT 17β-HYDROXYSTEROID DEGYDROGENASE (AKR1C3)
EA201891440A1 (en) COMPOSITIONS / COMPOSITIONS CONTAINING BTK INHIBITOR
EA201991798A1 (en) STORAGE STORAGE
EA201600288A1 (en) SUBSTITUTED PHYLALANINE DERIVATIVES
EA201791174A1 (en) ANTIMICOTIC CONNECTION
EA201600304A1 (en) APPLICATION OF SUBSTITUTED DIHYDROOXINDOLYL SULPHONAMIDES OR THEIR SALTS TO ENHANCE PLANT TOLERANCE TO STRESS
EA201891664A1 (en) COMPOSITIONS / COMPOSITIONS CONTAINING BTK INHIBITOR
MX2022010466A (en) Combination treatment for hematological cancers.
EA202190810A1 (en) METHODS AND KITS FOR OBTAINING WHOLE BLOOD WITH INACTIVATED PATHOGEN
EA201791819A1 (en) COMBINED THERAPY WITH ANTIBODY CONJUGATE AGAINST CD19 WITH MEDICINE AND VINCRISTINE
EA202090266A1 (en) MPO INHIBITORS FOR MEDICAL USE
CL2020000586A1 (en) Modulators of enac expression.